AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EDITAS MEDICINE, INC. AND JUNO THERAPEUTICS, INC. May 3, 2018Collaboration and License Agreement • August 7th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 3, 2018 (the “Amendment Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 11 Hurley St, Cambridge, MA 02141 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”) and amends and restates that certain Collaboration and License Agreement by and between Editas and Juno (the “Original Agreement”) dated as of May 26, 2015 (the “Original Agreement Effective Date”).
Sponsored Research AgreementSponsored Research Agreement • August 7th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Sponsored Research Agreement (this “Agreement”), dated as of June 7, 2018 (the “Effective Date”), is made by and between the Broad Institute, Inc. (“Broad”), a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142, and Editas Medicine, Inc. (“Company”), a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, Massachusetts 02141. Each of Broad and Company may be referred to herein as a “Party” or together as the “Parties.”
